NEWTON, Mass., and TUCSON, Ariz., Nov. 14, 2013 — Halo Therapeutics LLC and the Muscular Dystrophy Association (MDA) today announced that $500,000 has been awarded for development of the experimental drug HT-100 as a treatment for Duchenne muscular dystrophy (DMD).
MDA supported development of utrophin-boosting compounds for years
TUCSON, Ariz. — The Muscular Dystrophy Association announced today that SMT C1100, an experimental drug for Duchenne muscular dystrophy (DMD), has been found safe in healthy human volunteers and reached blood levels potentially adequate for a therapeutic benefit. Next steps are to move into trials in people with DMD.
TARRYTOWN, N.Y. and TUCSON, Ariz., April17, 2013 — ARMGO Pharma and the Muscular Dystrophy Association (MDA) today announced that $1 million has been awarded for preclinical work in support of an investigational new drug (IND) application with the U.S.